Metabolic•FDA Approved

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is the first "twincretin" medication, offering superior weight loss and glycemic control compared to GLP-1 mono-agonists.

Mechanism of Action

Activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP activation synergizes with GLP-1 to enhance insulin secretion and improve fat metabolism.

Key Benefits

Superior weight loss vs Semaglutide
Improved insulin sensitivity
Reduced visceral fat
Lower risk of hypoglycemia

Research Protocol

Loading Phase
2.5mg weekly for 4 weeks
Maintenance
Titrate up to 15mg weekly
Dual mechanism often results in better tolerability than pure GLP-1s for some users.

Chemical Properties

FormulaC225H348N48O68
Mol. Weight4813.53 g/mol

Side Effects & Risks

  • •Nausea
  • •Diarrhea
  • •Decreased appetite
  • •Dyspepsia

Amino Acid Sequence

39-amino acid linear synthetic peptide
HomeLibraryResearchFavoritesToolsVisuals